You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Repurposing Pyrvinium as an Orphan Drug for Familial Adenomatous Polyposis

    SBC: Stemsynergy Therapeutic            Topic: 102

    DESCRIPTION provided by applicant The tumor suppressor Adenomatous Polyposis Coli APC directs degradation of catenin a central signaling protein in the WNT pathway Germline loss of function mutations in APC activate WNT signaling and underlie the inherited colorectal cancer predisposition syndrome Familial Adenomatous Polyposis FAP an orphan disease while somatic mutations lead to spo ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  2. Temozolomide Perillyl Alcohol Conjugate as Treatment for Recurrent Malignant Brain tumors

    SBC: NEONC TECHNOLOGIES INC            Topic: BT

    DESCRIPTION provided by applicant Glioblastoma multiforme GBM the most common and malignant of all gliomas has a median survival time of months Standard of care chemotherapy using temozolomide TMZ is effective initially but the GBM inevitably recurs and these recurrent tumors are resistant to TMZ There are currently no effective treatment options for patients with TMZ resistant ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  3. Bone targeted antimicrobials for biofilm-mediated osteolytic infection treatment

    SBC: BIOVINC, LLC            Topic: NIDCR

    DESCRIPTION provided by applicant Infectious bone disease is a major cause of morbidity and mortality worldwide Successful treatment often requires surgical intervention with longer term antibiotic therapy Bacterial biofilm pathogens are associated with most osseous infections and represent a major target of therapy The biofilm pathogens associated with chronic bone infections bind to and co ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  4. PlusOne: Prototyping and Validation of a Wireless In-Home Breathing Monitor for Prevention of Overdose Deaths

    SBC: Xandem Technology LLC            Topic: NIDA

    DESCRIPTION provided by applicant This proposal investigates the use of a novel passive personal monitoring system to stem the tide in the epidemic of deaths due to unintentional opioid drug overdoses In the U S in opioid drug overdoses including prescription pain relievers and heroin caused deaths a number that has increased dramatically over the past two decades A person w ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  5. High-potency nitro antimicrobials for topical treatment of trichomoniasis

    SBC: DESIGNMEDIX, INC.            Topic: R

    DESCRIPTION provided by applicant Trichomonas vaginalis is the causative agent of the most common non viral sexually transmitted infection with million new cases reported annually in the world and million cases in the U S In addition to infections of the urogenital tract trichomoniasis increases the risk of adverse pregnancy outcomes and HIV transmission and increases the incidence ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  6. Development of DRα1-MOG-35-55 for treatment of DR2 negative MS subjects

    SBC: VIROGENOMICS BIODEVELOPMENT INC            Topic: NIAID

    DESCRIPTION provided by applicant Our laboratory discovered and is developing partial p MHC class II constructs pMHC as a possible immunotherapy for multiple sclerosis MS pMHC containing the extracellular domains of the MS risk factor HLA DR linked covalently to the encephalitogenic peptide of myelin oligodendrocyte glycoprotein pDR MOG can reverse CNS inflammation and ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  7. An epitope focused nanoparticle vaccine for MRSA and biodefense

    SBC: VLP BIOTECH, INC.            Topic: NIAID

    DESCRIPTION provided by applicant Overall Staphylococcus aureus is a gram positive bacteria which possesses a multitude of virulence factors It is a frequent and severe pathogen in hospitals and of increasing concern in the community where it results in severe skin infections pneumonia bacterial endocarditis and sepsis A significant proportion of these infections are the result of methici ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  8. "Extra Innings”: Using Serious Gaming and the Science of Baseball to Teach Science and Mathematics

    SBC: DFUSION INC.            Topic: 999

    DESCRIPTION provided by applicant Due to the rapid advances in science technology engineering and mathematics STEM the United States has been at the forefront of innovation and technology development in the science health and biomedical fields However these continuing advances are in jeopardy as there is a growing national shortage of trained STEM workers While the need for a STEM li ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  9. Modulation of the Innate Immune Response by Fisetin Derivatives for the Treatment of AD

    SBC: VIROGENICS, INC.            Topic: NIAID

    DESCRIPTION provided by applicant There are currently no drugs or other therapeutic interventions that can reverse or halt the progression of Alzheimerandapos s disease AD Age is by far the greatest risk factor for AD and it is known from studies in both mice and humans that neuroinflammation is increased with old age and to an even greater extent in AD Therefore a drug that could reduce ...

    STTR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
  10. Clinical Text Automatic De-Identification to Support Large Scale Data Reuse and Sharing

    SBC: Clinacuity, Inc            Topic: 400

    DESCRIPTION provided by applicant The adoption of Electronic Health Record EHR systems is growing at a fast pace in the U S and this growth results in very large quantities of patient clinical data becoming available in electronic format with tremendous potentials but also equally growing concern for patient confidentiality breaches Secondary use of clinical data is essential to fulfill ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government